作者
Raphael Itzykson, Elise Fournier, Celine Berthon, Christoph Röllig, Thorsten Braun, Alice Marceau-Renaut, Cecile Pautas, Olivier Nibourel, Emilie Lemasle, Jean-Baptiste Micol, Lionel Ades, Delphine Lebon, Jean-Valere Malfuson, Lauris Gastaud, Laure Goursaud, Emmanuel Raffoux, Kevin-James Wattebled, Philippe Rousselot, Xavier Thomas, Sylvain Chantepie, Thomas Cluzeau, Hubert Serve, Nicolas Boissel, Christine Terre, Karine Celli-Lebras, Claude Preudhomme, Christian Thiede, Herve Dombret, Claude Gardin, Nicolas Duployez
发表日期
2021/8/19
期刊
Blood, The Journal of the American Society of Hematology
卷号
138
期号
7
页码范围
507-519
出版商
American Society of Hematology
简介
To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute Leukemia French Association) study (median age, 68 years). Mutation patterns and OS differed between the 84 patients with poor-risk cytogenetics and the 387 patients with good (n = 13), intermediate (n = 339), or unmeasured (n = 35) cytogenetic risk. TP53 (hazards ratio [HR], 2.49; P = .0003) and KRAS (HR, 3.60; P = .001) mutations independently worsened the OS of patients with poor-risk cytogenetics. In those without poor-risk cytogenetics, NPM1 (HR, 0.57; P = .0004), FLT3 internal tandem duplications with low (HR, 1.85; P = .0005) or high (HR, 3.51; P < 10−4) allelic ratio, DNMT3A (HR, 1.86; P < 10−4), NRAS (HR, 1.54; P = .019), and ASXL1 (HR, 1.89; P = .0003 …
学术搜索中的文章
R Itzykson, E Fournier, C Berthon, C Röllig, T Braun… - Blood, The Journal of the American Society of …, 2021